Trial Profile
A Phase II Study of CCI-779 in Patients With Relapsed, Refractory or Transformed Chronic Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 23 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 01 Sep 2005 New trial record.